These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns. The post 2 cheap shares that could be takeover targets in 2025 ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CrowdStrike is back near highs despite crashing in July. Why Raymond James' David Cox calls it "immediately suspicious." ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Tesla stock has had an incredible run, but is well off its all time high reached on Dec. 17. Investors might need some more ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...